HSK41959 / Haisco - LARVOL DELTA

First-in-human phase I study of HSK41959, an MTA-cooperative PRMT5 inhibitor, in patients with MTAP-deleted advanced solid tumors (ESMO 2026) - No abstract available

Clinical • First-in-human • Metastases • P1 data • Oncology • Solid Tumor • MTAP

HSK41959 With Standard Therapy in Solid Tumors With MTAP Deletion (clinicaltrials.gov) - P1 | N=258 | Not yet recruiting | Sponsor: Haisco Pharmaceutical Group Co., Ltd.

New P1 trial • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Pancreatic Cancer • Solid Tumor • MTAP

First-in-human phase I study of HSK41959, an MTA-cooperative PRMT5 inhibitor, in patients with MTAP -deleted advanced solid tumors. (ASCO 2026) - P1 | "HSK41959 is well tolerated without unexpected safety issues. Preliminary efficacy data demonstrate favorable activity of HSK41959 in patients with MTAP-deleted solid tumors."

Clinical • First-in-human • Metastases • P1 data • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • MTAP

HSK41959-2: An oral MTA-cooperative PRMT5 inhibitor for MTAP deleted cancer (AACR 2024) - "Meanwhile in the HCT116 MTAP-WT xenograft model, HSK41959-2 did not show tumor growth inhibition at 100 mpk. In conclusion, HSK41959-2 is a promising oral MTA-cooperative PRMT5 inhibitor, it was nominated as a development candidate."

Oncology • CD34 • MTAP

Phase I Study of HSK41959 in Solid Tumors With MTAP Deletion (clinicaltrials.gov) - P1 | N=245 | Recruiting | Sponsor: Haisco Pharmaceutical Group Co., Ltd.

New P1 trial • Solid Tumor